Opus Genetics, Inc. (IRD) Doses First Participant in Phase 1/2 Gene Therapy Trial
Opus Genetics (IRD) dosed the first participant in its Phase 1/2 trial for OPGx-RDH12, a gene therapy for RDH12-associated Leber congenital amaurosis. This is the company's third gene therapy in clinical development, following IND clearance in October 2026. No clinical results were reported.

